SCHEMBL12247403

SCHEMBL12247403

CC1(C#N)CCc2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 15/20 0.43
KDM1A O60341 2/20 0.42
MAOB P27338 1/20 0.42
ALDH1A1 P00352 2/20 0.41
TP53 P04637 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
TSHR P16473 1/20 0.41
CYP2C19 P33261 1/20 0.41
EBP Q15125 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL779686 0.89 KDM1A (0.51) SIGMAR1KDM1ATP53CYP1A2CYP3A4
SCHEMBL30128211 0.80 ALDH1A1 (0.39) ALDH1A1
SCHEMBL11742012 0.80 ALDH1A1 (0.39) ALDH1A1
SCHEMBL23715380 0.78 OPRM1 (0.36) SIGMAR1KDM1AALDH1A1CYP1A2CYP3A4
SCHEMBL19469638 0.77 ALDH1A1 (0.41) SIGMAR1ALDH1A1CYP3A4
SCHEMBL30058891 0.77 KDM1A (0.46) KDM1A
SCHEMBL23704864 0.77 KDM1A (0.46) KDM1A
SCHEMBL17231962 0.75 SIGMAR1 (0.36) SIGMAR1KDM1AALDH1A1
SCHEMBL17231961 0.75 SIGMAR1 (0.36) SIGMAR1ALDH1A1
SCHEMBL10772805 0.74 RARB (0.33) ALDH1A1TP53CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9884844-B2 Heterocyclic compounds and methods of use thereof SUNOVION PHARMACEUTICALS, INC. (US) 2018-02-06 US disclosed
US-20150336928-A1 Heterocyclic Compounds And Methods Of Use Thereof SUNOVION PHARMACEUTICALS INC. 2015-11-26 US disclosed
US-8921359-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
WO-2014106238-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FANG, QUN, KEVIN (US) 2014-07-03 WO disclosed
EP-2681206-A1 MST1 KINASE INHIBITORS AND METHODS OF THEIR USE Lexicon Pharmaceuticals, Inc. (US) 2014-01-08 EP disclosed
US-8450308-B2 Inhibitors of beta-secretase VITAE PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-8309739-B2 Chemical compounds SYNGENTA LIMITED (GB) 2012-11-13 US disclosed
WO-2012121992-A1 MST1 KINASE INHIBITORS AND METHODS OF THEIR USE LEXICON PHARMACEUTICALS, INC. (US) 2012-09-13 WO disclosed
US-20110218341-A1 CHEMICAL COMPOUNDS SYNGENTA CROP PROTECTION, INC. (US) 2011-09-08 US disclosed
US-20110218192-A1 Inhibitors Of Beta-Secretase VITAE PHARMACEUTICALS, INC. (US) 2011-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218192-A1 Inhibitors Of Beta-Secretase BACE1, BACE2, APP SIGMAR1 4018/4885KDM1A 2831/4885MAOB 681/4885
US-20150336928-A1 Heterocyclic Compounds And Methods Of Use Thereof GRIN2C, COMT, NLN SIGMAR1 882/4885KDM1A 3995/4885MAOB 6/4885
US-20110218341-A1 CHEMICAL COMPOUNDS OR10J3, NR0B1, NR0B2 SIGMAR1 391/4885KDM1A 2282/4885MAOB 1946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.